XBiotech Provides Update on Phase III Oncology Study in Europe By: Benzinga via Benzinga November 23, 2015 at 18:05 PM EST XBiotech (NASDAQ: XBIT), developer of True Human™ therapeutic antibodies, announced today findings related to enrollment in the study. ... Read More >> Related Stocks: Xbiotech Inc